Joseph Catanzaro's questions to Schrodinger Inc (SDGR) leadership • Q3 2024
Question
Joseph Catanzaro of Piper Sandler inquired about the clinical validation of the PRMT5 target from competitor data and how Schrodinger's program aims to differentiate.
Answer
President of R&D Karen Akinsanya acknowledged that competitor data shows PRMT5 is an exciting mechanism with broad monotherapy activity. She stated Schrodinger's program aims for a best-in-class profile by focusing on brain penetrance to target tumors like glioblastoma, an improved DDI profile for combinations, and a novel angle to maximize synergy between PRMT5 and MTA for deeper responses.